Obeticholic acid may increase the risk of gallstone formation in susceptible patients
S Al-Dury, A Wahlström, K Panzitt, A Thorell… - Journal of …, 2019 - Elsevier
Background & Aims The nuclear farnesoid X receptor (FXR) agonist obeticholic acid (OCA)
has been developed for the treatment of liver diseases. We aimed to determine whether …
has been developed for the treatment of liver diseases. We aimed to determine whether …
Obeticholic acid may increase the risk of gallstone formation in susceptible patients
S Al-Dury, A Wahlström, K Panzitt, A Thorell… - 2019 - pubmed.ncbi.nlm.nih.gov
Background & aims The nuclear farnesoid X receptor (FXR) agonist obeticholic acid (OCA)
has been developed for the treatment of liver diseases. We aimed to determine whether …
has been developed for the treatment of liver diseases. We aimed to determine whether …
Obeticholic acid may increase the risk of gallstone formation in susceptible patients
S Al-Dury, A Wahlström, K Panzitt, A Thorell… - Journal of …, 2019 - Elsevier
Background & Aims The nuclear farnesoid X receptor (FXR) agonist obeticholic acid (OCA)
has been developed for the treatment of liver diseases. We aimed to determine whether …
has been developed for the treatment of liver diseases. We aimed to determine whether …
Obeticholic acid may increase the risk of gallstone formation in susceptible patients
S Al-Dury, A Wahlström, K Panzitt… - Journal of …, 2019 - journal-of-hepatology.eu
Background & Aims The nuclear farnesoid X receptor (FXR) agonist obeticholic acid (OCA)
has been developed for the treatment of liver diseases. We aimed to determine whether …
has been developed for the treatment of liver diseases. We aimed to determine whether …
[PDF][PDF] Obeticholic acid may increase the risk of gallstone formation in susceptible patients
S Al-Dury, A Wahlström, K Panzitt, L Fändriks… - 2019 - researchgate.net
Background & Aims: The nuclear farnesoid X receptor (FXR) agonist obeticholic acid (OCA)
has been developed for the treatment of liver diseases. We aimed to determine whether …
has been developed for the treatment of liver diseases. We aimed to determine whether …
Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
S Al-Dury, A Wahlström, K Panzitt, A Thorell… - Journal of …, 2019 - europepmc.org
Methods Twenty patients awaiting laparoscopic cholecystectomy were randomized to
treatment with OCA (25 mg/day) or placebo for 3 weeks until the day before surgery. Serum …
treatment with OCA (25 mg/day) or placebo for 3 weeks until the day before surgery. Serum …
Obeticholic acid may increase the risk of gallstone formation in susceptible patients
S Al-Dury, A Wahlström, K Panzitt… - Journal of …, 2019 - journal-of-hepatology.eu
Background & Aims The nuclear farnesoid X receptor (FXR) agonist obeticholic acid (OCA)
has been developed for the treatment of liver diseases. We aimed to determine whether …
has been developed for the treatment of liver diseases. We aimed to determine whether …